Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab

Journal of the American College of Cardiology

Volumn 63, Issue 8, 2014, Pages 809-816

  Ky, Bonnie ^a   Putt, Mary ^a   Sawaya, Heloisa ^b   French, Benjamin ^a   Januzzi Jr , James L ^b   Sebag, Igal A ^c   Plana, Juan Carlos ^d   Cohen, Victor ^e   Banchs, Jose ^f   Carver, Joseph R ^a   Wiegers, Susan E ^g   Martin, Randolph P ^h   Picard, Michael H ^b   Gerszten, Robert E ^b   Halpern, Elkan F ⁱ   Passeri, Jonathan ^b   Kuter, Irene ⁱ   Scherrer Crosbie, Marielle ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g TEMPLE UNIVERSITY   (United States)

^h PIEDMONT HEART INSTITUTE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cardio oncology; chemotherapy cardiotoxicity; trastuzumab cardiotoxicity

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GALECTIN; GROWTH DIFFERENTIATION FACTOR 15; MYELOPEROXIDASE; PACLITAXEL; PLACENTAL GROWTH FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; TROPONIN I; VASCULOTROPIN RECEPTOR 1; GALECTIN 3;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HER2 POSITIVE BREAST CANCER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; CANCER CHEMOTHERAPY; ECHOCARDIOGRAPHY; HAZARD RATIO; LABORATORY TEST; RISK ASSESSMENT;

CARDIO-ONCOLOGY; CHEMOTHERAPY CARDIOTOXICITY; TRASTUZUMAB CARDIOTOXICITY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; PEROXIDASE; PREDICTIVE VALUE OF TESTS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 84896720397     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.10.061     Document Type: Article

References (25)

1. A. Seidman, C. Hudis, and M.K. Pierri et al. Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221 (Pubitemid 34177427)
2. T.M. Suter, M. Procter, and D.J. van Veldhuisen et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial J Clin Oncol 25 2007 3859 3865 (Pubitemid 47477261)
3. D. Slamon, W. Eiermann, and N. Robert et al. Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
4. E.J. Bowles, R. Wellman, and H.S. Feigelson et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study J Natl Cancer Inst 104 2012 1293 1305
5. R. Altena, P.J. Perik, D.J. van Veldhuisen, E.G. de Vries, and J.A. Gietema Cardiovascular toxicity caused by cancer treatment: strategies for early detection Lancet Oncol 10 2009 391 399
6. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879 (Pubitemid 36605157)
7. B.V. Jensen, T. Skovsgaard, and S.L. Nielsen Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients Ann Oncol 13 2002 699 709 (Pubitemid 34567375)
8. E. Braunwald Biomarkers in heart failure N Engl J Med 358 2008 2148 2159
9. B. Ky, B. French, and W.C. Levy et al. Multiple biomarkers for risk prediction in chronic heart failure Circ Heart Fail 5 2012 183 190
10. B. Zethelius, L. Berglund, and J. Sundstrom et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes N Engl J Med 358 2008 2107 2116 (Pubitemid 351679597)
11. H. Sawaya, I.A. Sebag, and J.C. Plana et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
12. H. Sawaya, I.A. Sebag, and J.C. Plana et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab Circ Cardiovasc Imaging 5 2012 596 603
13. R.M. Lang, M. Bierig, and R.B. Devereux et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group J Am Soc Echocardiogr 18 2005 1440 1463
14. G. Gomez, M.L. Calle, R. Oller, and K. Lanohr Tutorial on methods for interval-censored data and their implementation in R Stat Modeling 9 2009 249 297
15. D. Cardinale, M.T. Sandri, and A. Colombo et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754 (Pubitemid 38737923)
16. D. Cardinale, A. Colombo, and R. Torrisi et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
17. P.G. Morris, C. Chen, and R. Steingart et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib Clin Cancer Res 17 2011 3490 3499
18. S. Baldus, C. Heeschen, and T. Meinertz et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 108 2003 1440 1445 (Pubitemid 37176448)
19. T. Reichlin, T. Socrates, and P. Egli et al. Use of myeloperoxidase for risk stratification in acute heart failure Clin Chem 56 2010 944 951
20. W.H. Tang, W. Tong, and R.W. Troughton et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure J Am Coll Cardiol 49 2007 2364 2370 (Pubitemid 46891707)
21. Y.J. Kang, Y. Chen, and P.N. Epstein Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice J Biol Chem 271 1996 12610 12616 (Pubitemid 26160936)
22. S.E. Lipshultz, H. Cohen, S.D. Colan, and E.H. Herman The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity Leuk Lymphoma 47 2006 1454 1458 (Pubitemid 44364007)
23. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 2010 826 832
24. K.C. Wollert, T. Kempf, and B. Lagerqvist et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome Circulation 116 2007 1540 1548 (Pubitemid 47511417)
25. V.C. Vasile, A.K. Saenger, J.M. Kroning, G.G. Klee, and A.S. Jaffe Biologic variation of a novel cardiac troponin I assay Clin Chem 57 2011 1080 1081